2015
DOI: 10.18632/oncoscience.142
|View full text |Cite
|
Sign up to set email alerts
|

Uncovering potential downstream targets of oncogenic GRPR overexpression in prostate carcinomas harboring ETS rearrangements

Abstract: Gastrin-releasing peptide receptor (GRPR) is known to be overexpressed in several human malignancies, including prostate cancer, and has been implicated in multiple important neoplastic signaling pathways. We recently have shown that GRPR is an ERG and ETV1 target gene in prostate cancer, using a genome-wide scale and exon-level expression microarray platform. Due to its cellular localization, the relevance of its function and the availability of blocking agents, GRPR seems to be a promising candidate as thera… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
13
0

Year Published

2015
2015
2021
2021

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 13 publications
(13 citation statements)
references
References 32 publications
0
13
0
Order By: Relevance
“…This change could reduce cancer cell movement and invasion. Similarly, silencing of GRPr signaling led to a marked reduction in the malignant phenotype of the human VCaP and LNCaP prostate cancer cell lines by decreasing cell proliferation, invasion, and the capacity to grow in the absence of cell–cell attachment [43]. …”
Section: Discussionmentioning
confidence: 99%
“…This change could reduce cancer cell movement and invasion. Similarly, silencing of GRPr signaling led to a marked reduction in the malignant phenotype of the human VCaP and LNCaP prostate cancer cell lines by decreasing cell proliferation, invasion, and the capacity to grow in the absence of cell–cell attachment [43]. …”
Section: Discussionmentioning
confidence: 99%
“…For the analysis of HOXB13 mRNA expression levels in tumor and normal prostate tissue (NPT) samples, cDNA was synthetized using the TransPlex Whole Transcriptome Amplification kit (Sigma-Aldrich, St Louis, MO, USA), as previously described [45]. HOXB13 primers and probe (primer forward: 5´-GTTGCCAGGGAGAACAGAAC-3´; primer reverse: 5´-TGTACGGAATGCGTTTCTTG-3´; Taqman probe: 5´Fam-AAGGCAGCATTTGCAGACTCCAGC-3´Tamra) were designed using the Primer3 software (v.0.4.0) [46] and acquired from Metabion (Martinsried, Germany).…”
Section: Methodsmentioning
confidence: 99%
“…In vitro studies with overexpressed JAKs revealed that aberrant TYK2 levels lead to cellular transformation with constitutive phosphorylation of STAT3 [34]. An unusually high expression of TYK2 associated with or causative for carcinogenesis (reviewed [35]) was described for various cancer cell lines and samples from patients suffering from prostate [36,37], ovarian [38], cervical [39], and breast cancer [40,41], as well as malignant peripheral nerve sheath tumors (MPNST) [42,43]. Conflictingly, lowered TYK2 levels in tumor samples and sections (tumor cells and stroma) are generally considered to be an unfavorable prognostic marker (e.g., [44], ).…”
Section: Aberrant Expression And/or Activity Of Tyk2 In Cancersmentioning
confidence: 99%